<DOC>
	<DOC>NCT01046539</DOC>
	<brief_summary>This is a single site, double-blind, randomized, placebo-controlled, crossover study to assess the pharmacodynamics (PD) of RDC-0313 coadministered with buprenorphine in 12 healthy, opioid-experienced, non-treatment-seeking subjects.</brief_summary>
	<brief_title>Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>ALKS-33</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Subject must be capable of understanding and complying with the protocol and has signed the informed consent Must be 1855 years of age Must have a body mass index of 18.030.0 kg/m2 at screening Female subjects must agree to use an acceptable method of contraception from date of consent and until two weeks after the last dose Subjects must be willing not to use alcohol, tobacco, caffeine, or xanthinecontaining products while resident at inpatient facility Subjects must be an experienced opioid user who meets the following criteria: 1) has used opioids for nontherapeutic purposes (ie, for psychoactive effects) on at least 10 occasions in the past five years; 2) has used opioids at least 2 times in the two years prior to screening; and 3) is not physically dependent on opioids, as assessed by medical history and naloxone challenge performed at screening Must not have any current or piror significant hepatic, renal, endocrine, cardiac, nervous, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic disorders. Must not have current or past opioid, alcohol, or other durg dependence (excluding nicotine and caffeine) or showing signs of withdrawal following the naloxone (Narcan) challenge. Please contact site for additional information about other exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>